BACKGROUND: The triple-negative breast cancer (TNBC) constitutes a heterogeneous disease with an aggressive behavior and a poor prognosis. A better understanding of its biology is required to identify new biomarkers and improve clinical outcomes. SUMMARY: To date, the definition and classification of TNBC depends on a multiomic approach including immunohistochemistry (IHC), genomic, and transcriptomic features, and the tumor immune landscape. The development of new technologies has allowed us to sequence the whole cancer genome. The Cancer Genome Atlas (TCGA) and next-generation sequencing have led to a greater knowledge of DNA alterations such as TP53 or BRCA mutations, copy number variations, and DNA methylations. In addition, gene expression profiling has allowed to define a molecular intrinsic classification of TNBC based on mRNA. IHC and genomic profiling are also necessary to identify new immune biomarkers such as the presence of tumor-infiltrating lymphocytes and the expression of immune checkpoint molecules. KEY MESSAGES: This review aimed to provide recent knowledge of TNBC biology and classification focused on IHC, transcriptomics, genomic features, and the new immune biomarkers.
BACKGROUND: The triple-negative breast cancer (TNBC) constitutes a heterogeneous disease with an aggressive behavior and a poor prognosis. A better understanding of its biology is required to identify new biomarkers and improve clinical outcomes. SUMMARY: To date, the definition and classification of TNBC depends on a multiomic approach including immunohistochemistry (IHC), genomic, and transcriptomic features, and the tumor immune landscape. The development of new technologies has allowed us to sequence the whole cancer genome. The Cancer Genome Atlas (TCGA) and next-generation sequencing have led to a greater knowledge of DNA alterations such as TP53 or BRCA mutations, copy number variations, and DNA methylations. In addition, gene expression profiling has allowed to define a molecular intrinsic classification of TNBC based on mRNA. IHC and genomic profiling are also necessary to identify new immune biomarkers such as the presence of tumor-infiltrating lymphocytes and the expression of immune checkpoint molecules. KEY MESSAGES: This review aimed to provide recent knowledge of TNBC biology and classification focused on IHC, transcriptomics, genomic features, and the new immune biomarkers.
Authors: Clare Stirzaker; Elena Zotenko; Jenny Z Song; Wenjia Qu; Shalima S Nair; Warwick J Locke; Andrew Stone; Nicola J Armstong; Mark D Robinson; Alexander Dobrovic; Kelly A Avery-Kiejda; Kate M Peters; Juliet D French; Sandra Stein; Darren J Korbie; Matt Trau; John F Forbes; Rodney J Scott; Melissa A Brown; Glenn D Francis; Susan J Clark Journal: Nat Commun Date: 2015-02-02 Impact factor: 14.919
Authors: Joshua A Bauer; A Bapsi Chakravarthy; Jennifer M Rosenbluth; Deming Mi; Erin H Seeley; Nara De Matos Granja-Ingram; Maria G Olivares; Mark C Kelley; Ingrid A Mayer; Ingrid M Meszoely; Julie A Means-Powell; Kimberly N Johnson; Chiaojung Jillian Tsai; Gregory D Ayers; Melinda E Sanders; Robert J Schneider; Silvia C Formenti; Richard M Caprioli; Jennifer A Pietenpol Journal: Clin Cancer Res Date: 2010-01-12 Impact factor: 12.531
Authors: C Criscitiello; M A Bayar; G Curigliano; F W Symmans; C Desmedt; H Bonnefoi; B Sinn; G Pruneri; C Vicier; J Y Pierga; C Denkert; S Loibl; C Sotiriou; S Michiels; F André Journal: Ann Oncol Date: 2018-01-01 Impact factor: 32.976
Authors: S J Luen; R Salgado; M V Dieci; A Vingiani; G Curigliano; R E Gould; C Castaneda; T D'Alfonso; J Sanchez; E Cheng; E Andreopoulou; M Castillo; S Adams; S Demaria; W F Symmans; S Michiels; S Loi Journal: Ann Oncol Date: 2019-02-01 Impact factor: 32.976
Authors: Dawn R Cochrane; Sebastián Bernales; Britta M Jacobsen; Diana M Cittelly; Erin N Howe; Nicholas C D'Amato; Nicole S Spoelstra; Susan M Edgerton; Annie Jean; Javier Guerrero; Francisco Gómez; Satyanarayana Medicherla; Iván E Alfaro; Emma McCullagh; Paul Jedlicka; Kathleen C Torkko; Ann D Thor; Anthony D Elias; Andrew A Protter; Jennifer K Richer Journal: Breast Cancer Res Date: 2014-01-22 Impact factor: 6.466
Authors: Carolin Hartung; Martin Porsch; Kathrin Stückrath; Sandy Kaufhold; Martin S Staege; Volker Hanf; Tilmann Lantzsch; Christoph Uleer; Susanne Peschel; Jutta John; Marleen Pöhler; Edith Weigert; Jörg Buchmann; Karl-Friedrich Bürrig; Kathleen Schüler; Daniel Bethmann; Ivo Große; Eva Johanna Kantelhardt; Christoph Thomssen; Martina Vetter Journal: Breast Care (Basel) Date: 2021-10-19 Impact factor: 2.860